EMD Serono and Fast Forward form research collaboration
Proposals will be jointly developed by EMD Serono and Fast Forward. Merck KGaA, the parent corporation of EMD Serono, will provide up to $19 million in funding. The
Johnson & Johnson (J&J) has agreed to purchase Firefly Bio for $1bn in cash, aiming to strengthen its oncology pipeline with Firefly Bio’s proprietary Firelink degrader-antibody conjugate (DAC) platform.